期刊文献+

国产和进口坎地沙坦酯片人体生物等效性评价 被引量:6

Studies on Bioequivalence of Candesartan Cilexetil Tablets in Healthy Volunteers
下载PDF
导出
摘要 目的评价国产和进口坎地沙坦酯的人体生物等效性。方法18名健康男性志愿者随机交叉口服受试制剂国产坎地沙坦酯片和参比制剂进口坎地沙坦酯片16 mg,采用荧光高效液相色谱法测定血浆中药物浓度。结果受试制剂和参比制剂的t_(max)分别为(4.56±1.10)和(5.17±1.29)h;p_(max)分别为(161.5±50.8)和(148.0±41.3)mg·L^(-1);t_(V2)分别为(8.99±2.06)和(8.27±1.70)h;AUC_(0-48)分别为(1885.8±578.2)和(1863.7±443.8)μg·h·L^(-1);AUC_(0-∞)分别为(1950.1±592.3)和(1917.3±447.6)μg·h·L^(-1)。国产坎地沙坦酯片的相对生物利用度为(102.9±28.1)%。结论经统计学分析,国产坎地沙坦酯片与进口坎地沙坦酯片具有生物等效性。 OBJECTIVE To study the bioavailability of domestic candesartan cilexetil tablets and imported candesartan cilexetil tablets in healthy volunteers. METHODS A single oral dose of 16 mg domestic or imported candesartan cilexetil tablets was given respectively to 18 healthy male volunteers in a randomized crossover study. The plasma concentrations of candesartan cilexetil were deter- mined by SPE- HPLC. RESULTS The main pharmacokinetic parameters of the two products were as follows:tmax(4. 56 ± 1. 10) and (5. 17±1.29) h,ρmax(161.5 ±50.8) and (148.0±41.3) μg· L^-1, t1/2(8.99±2.06) and (8.27±1.70) h; AUC048(1 885.8± 578.2) and (1 863.7 ±443.8) μg· h·L^-1 ; AUC0-∞ (1 950. 1±592.3) and ( 1 917.3 ±447.6) μg · h · L^-1 ,respectively. The relative bioavailability of domestic to imported formulation was ( 102.9 ± 28.1 ) %. CONCLUSION Statistic analysis showed that the domestic and imported candesartan cilexetil tablets were bioequivalent.
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第6期455-458,共4页 Chinese Pharmaceutical Journal
关键词 坎地沙坦酯 高效液相色谱法 生物利用度 candesartan cilexetil HPLC bioavailability
  • 相关文献

参考文献8

  • 1WEIR M R, WEBER M A, NEUTEL J M, et al. Efficacy of candesartan cilexetil as add on therapy in hypertensive partients uncontrolled on background therapy : a clinical experience trial. ACTION Study Investigators[ J ]. Am J Hypertrns, 2001,14 (6 pt 1 ) :567-572. 被引量:1
  • 2YAMAMOTO S, KAWASHIMA T, KUNITAKE T. et al. The effects of replacing dihydropyridine calicum-channel blockers with angiotensin Ⅱ receptor blocker on the quality of life of hypertensive patients[J]. Blood Press Suppl, 2003, 2: 22-28. 被引量:1
  • 3GONZALEZ L, LOPEZ J A, ALONSO R M, et al. Fast screening method for the determination of angiotensin Ⅱ receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection[ J]. J Chromatogr A ,2002,949(1-2) :49-60. 被引量:1
  • 4HELENE S, PEROLOF L, CATHRINE A. Determination of candesartan cileetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection [ J ]. J Chromatogr B, 1999, 731 (9) : 411-417. 被引量:1
  • 5SFDA. The technique guidances of bioavailability and bioequivalance study of chemical preparations in human[S]. 2004:9. 被引量:1
  • 6FUCHS B, BREITHAUPT-GROGLER K, BELZ G G, et al. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man[J]. J Pharm Pharmacol,2000,52(9) :1075-1083. 被引量:1
  • 7HOOGKAMER J F, KLEINBLOESEM C H, OUWERKERK M, et al. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function[ J]. Eur J Clin Pharmacol, 1998,54 (4) :341-345. 被引量:1
  • 8GLEITER C H, MORIKE K E. Clinical pharmacokinetics of candesartan[ J]. Clin Pharmacokinet, 2002,41 ( 1 ) :7-17. 被引量:1

同被引文献47

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部